Cirrhosis Explained

Cirrhosis
Synonyms:Cirrhosis of the liver, hepatic cirrhosis
Field:Gastroenterology, Hepatology
Symptoms:Tiredness, itchiness, swelling in the lower legs, jaundice, easily bruising, fluid build-up in the abdomen
Complications:Spontaneous bacterial peritonitis, hepatic encephalopathy, dilated veins in the esophagus, liver cancer
Onset:Over months, years or decades
Duration:Long term
Causes:Alcoholic liver disease, hepatitis B, hepatitis C, non-alcoholic steatohepatitis (NASH)
Diagnosis:Blood tests, medical imaging, liver biopsy[1]
Prevention:Vaccination (such as for hepatitis B), avoiding alcohol, losing weight, exercising, low-carbohydrate diet, controlling hypertension and diabetes may help in those with NAFLD or NASH
Treatment:Depends on underlying cause[2]
Frequency:2.8 million (2015)
Deaths:1.3 million (2015)

Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, and end-stage liver disease, is a condition of the liver in which the normal functioning tissue, or parenchyma, is replaced with scar tissue (fibrosis) and regenerative nodules as a result of chronic liver disease.[3] [4] [5] Damage to the liver leads to repair of liver tissue and subsequent formation of scar tissue. Over time, scar tissue and nodules of regenerating hepatocytes can replace the parenchyma, causing increased resistance to blood flow in the liver's capillaries—the hepatic sinusoids[6] —and consequently portal hypertension, as well as impairment in other aspects of liver function.[3] [7] The disease typically develops slowly over months or years.

Stages of cirrhosis include compensated cirrhosis and decompensated cirrhosis.[8] Early symptoms may include tiredness, weakness, loss of appetite, unexplained weight loss, nausea and vomiting, and discomfort in the right upper quadrant of the abdomen.[9] As the disease worsens, symptoms may include itchiness, swelling in the lower legs, fluid build-up in the abdomen, jaundice, bruising easily, and the development of spider-like blood vessels in the skin.[9] The fluid build-up in the abdomen may develop into spontaneous infections. More serious complications include hepatic encephalopathy, bleeding from dilated veins in the esophagus, stomach, or intestines, and liver cancer.[10]

Cirrhosis is most commonly caused by alcohol-related liver disease, metabolic dysfunction–associated steatohepatitis (MASH – the progressive form of metabolic dysfunction–associated steatotic liver disease,[11] previously called non-alcoholic fatty liver disease or NAFLD[12]), heroin abuse,[13] chronic hepatitis B, and chronic hepatitis C.[9] [14] Heavy drinking over a number of years can cause alcoholic liver disease.[15] Liver damage has also been attributed to heroin usage over an extended period of time as well.[16] MASH has a number of causes, including obesity, high blood pressure, abnormal levels of cholesterol, type 2 diabetes, and metabolic syndrome.[17] Less common causes of cirrhosis include autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis that disrupts bile duct function, genetic disorders such as Wilson's disease and hereditary hemochromatosis, and chronic heart failure with liver congestion.[9]

Diagnosis is based on blood tests, medical imaging, and liver biopsy.[1] [18]

Hepatitis B vaccine can prevent hepatitis B and the development of cirrhosis from it, but no vaccination against hepatitis C is available. No specific treatment for cirrhosis is known, but many of the underlying causes may be treated by a number of medications that may slow or prevent worsening of the condition.[2] Hepatitis B and C may be treatable with antiviral medications. Avoiding alcohol is recommended in all cases. Autoimmune hepatitis may be treated with steroid medications.[18] Ursodiol may be useful if the disease is due to blockage of the bile duct.[18] Other medications may be useful for complications such as abdominal or leg swelling, hepatic encephalopathy, and dilated esophageal veins.[18] If cirrhosis leads to liver failure, a liver transplant may be an option.[17] Biannual screening for liver cancer using abdominal ultrasound, possibly with additional blood tests, is recommended[19] [20] due to the high risk of hepatocellular carcinoma arising from dysplastic nodules.[21]

Cirrhosis affected about 2.8 million people and resulted in 1.3 million deaths in 2015.[22] [23] Of these deaths, alcohol caused 348,000 (27%), hepatitis C caused 326,000 (25%), and hepatitis B caused 371,000 (28%).[23] In the United States, more men die of cirrhosis than women.[18] The first known description of the condition is by Hippocrates in the fifth century BCE.[24] The term "cirrhosis" was derived in 1819 from the Greek word "kirrhos", which describes the yellowish color of a diseased liver.[25]

Signs and symptoms

Cirrhosis can take quite a long time to develop, and symptoms may be slow to emerge. Some early symptoms include tiredness, weakness, loss of appetite, weight loss, and nausea. Early signs may also include redness on the palms known as palmer erythema.[26] People may also feel discomfort in the right upper abdomen around the liver.

As cirrhosis progresses, symptoms can include neurological changes. This can consist of cognitive impairments, confusion, memory loss, sleep disorders, and personality changes.Steatorrhea or presence of undigested fats in stool is also a symptom of cirrhosis.[27]

Worsening cirrhosis can cause a build-up of fluid in different parts of the body such as the legs (edema) and abdomen (ascites). Other signs of advancing disease include itchy skin, bruising easily, dark urine, and yellowing of the skin.

Liver dysfunction

These features are a direct consequence of liver cells not functioning:

Portal hypertension

Liver cirrhosis makes it hard for blood to flow in the portal venous system.[38] This resistance creates a backup of blood and increases pressure. This results in portal hypertension. Effects of portal hypertension include:

Other nonspecific signs

Some signs that may be present include changes in the nails (such as Muehrcke's lines, Terry's nails, and nail clubbing).[41] [42] Additional changes may be seen in the hands (Dupuytren's contracture) as well as the skin/bones (hypertrophic osteoarthropathy).

Advanced disease

As the disease progresses, complications may develop. In some people, these may be the first signs of the disease.

Causes

Cirrhosis has many possible causes, and more than one cause may be present. History taking is of importance in trying to determine the most likely cause.[1] Globally, 57% of cirrhosis is attributable to either hepatitis B (30%) or hepatitis C (27%).[45] [46] Alcohol use disorder is another major cause, accounting for about 20–40% of the cases.[46]

Common causes

Less common causes

Pathophysiology

The liver plays a vital role in the synthesis of proteins (for example, albumin, clotting factors and complement), detoxification, and storage (for example, of vitamin A and glycogen). In addition, it participates in the metabolism of lipids and carbohydrates.

Cirrhosis is often preceded by hepatitis and fatty liver (steatosis), independent of the cause. If the cause is removed at this stage, the changes are fully reversible.

The pathological hallmark of cirrhosis is the development of scar tissue that replaces normal tissue, which is normally organized into lobules. This scar tissue blocks the portal flow of blood through the organ, raising the blood pressure and disturbing normal function. Research has shown the pivotal role of the stellate cell, that normally stores vitamin A, in the development of cirrhosis. Damage to the liver tissue from inflammation leads to the activation of stellate cells, which increases fibrosis through the production of myofibroblasts, and obstructs hepatic blood flow.[57] In addition, stellate cells secrete TGF beta 1, which leads to a fibrotic response and proliferation of connective tissue. TGF-β1 have been implicated in the process of activating hepatic stellate cells (HSCs) with the magnitude of fibrosis being in proportion to increase in TGF β levels. ACTA2 is associated with TGF β pathway that enhances contractile properties of HSCs leading to fibrosis.[58] Furthermore, HSCs secrete TIMP1 and TIMP2, naturally occurring inhibitors of matrix metalloproteinases (MMPs), which prevent MMPs from breaking down the fibrotic material in the extracellular matrix.[59] [60]

As this cascade of processes continues, fibrous tissue bands (septa) separate hepatocyte nodules, which eventually replace the entire liver architecture, leading to decreased blood flow throughout. The spleen becomes congested, and enlarged, resulting in its retention of platelets, which are needed for normal blood clotting. Portal hypertension is responsible for the most severe complications of cirrhosis.

Diagnosis

The diagnosis of cirrhosis in an individual is based on multiple factors. Cirrhosis may be suspected from laboratory findings, physical exam, and the person's medical history. Imaging is generally obtained to evaluate the liver. A liver biopsy will confirm the diagnosis; however, is generally not required.

Imaging

Ultrasound is routinely used in the evaluation of cirrhosis. It may show a small and shrunken liver in advanced disease. On ultrasound, there is increased echogenicity with irregular appearing areas.[61] Other suggestive findings are an enlarged caudate lobe, widening of the fissures and enlargement of the spleen.[62] An enlarged spleen, which normally measures less than in adults, may suggest underlying portal hypertension.[63] Ultrasound may also screen for hepatocellular carcinoma and portal hypertension. This is done by assessing flow in the hepatic vein. An increased portal vein pulsatility may be seen. However, this may be a sign of elevated right atrial pressure.[64] Portal vein pulsatility are usually measured by a pulsatility indices (PI). A number above a certain values indicates cirrhosis (see table below).

Pulsatility indices (PI)! Index !! Calculation !! Cutoff
Average-based (Max – Min) / Average[65] 0.5
Max-relative (Max – Min) / Max[66] 0.5[67] –0.54
Other scans include CT of the abdomen and MRI. A CT scan is non-invasive and may be helpful in the diagnosis. Compared to the ultrasound, CT scans tend to be more expensive. MRI provides excellent evaluation; however, is a high expense.

Cirrhosis is also diagnosable through a variety of new elastography techniques.[68] [69] When a liver becomes cirrhotic it will generally become stiffer. Determining the stiffness through imaging can determine the location and severity of disease. Techniques include transient elastography, acoustic radiation force impulse imaging, supersonic shear imaging and magnetic resonance elastography.[70] Transient elastography and magnetic resonance elastography can help identify the stage of fibrosis.[71] Compared to a biopsy, elastography can sample a much larger area and is painless.[72] It shows a reasonable correlation with the severity of cirrhosis. Other modalities have been introduced which are incorporated into ultrasonagraphy systems. These include 2-dimensional shear wave elastography and point shear wave elastography which uses acoustic radiation force impulse imaging.

Rarely are diseases of the bile ducts, such as primary sclerosing cholangitis, causes of cirrhosis. Imaging of the bile ducts, such as ERCP or MRCP (MRI of biliary tract and pancreas) may aid in the diagnosis.

Lab findings

The best predictors of cirrhosis are ascites, platelet count < 160,000/mm3, spider angiomata, and a Bonacini cirrhosis discriminant score greater than 7 (as the sum of scores for platelet count, ALT/AST ratio and INR as per table).[73]

Bonacini score[74]
Score Platelet count x109 ALT/AST ratio INR
0 >340 >1.7 <1.1
1 280-340 1.2-1.7 1.1-1.4
2 220-279 0.6-1.19 >1.4
3 160–219 <0.6 ...
4 100-159 ... ...
5 40-99 ... ...
6 <40 ... ...

These findings are typical in cirrhosis:

FibroTest is a biomarker for fibrosis that may be used instead of a biopsy.[78]

Other laboratory studies performed in newly diagnosed cirrhosis may include:

Markers of inflammation and immune cell activation are typically elevated in cirrhotic patients, especially in the decompensated disease stage:

A recent study identified 15 microbial biomarkers from the gut microbiota.[86] These could potentially be used to discriminate patients with liver cirrhosis from healthy individuals.

Pathology

The gold standard for diagnosis of cirrhosis is a liver biopsy. This is usually carried out as a fine-needle approach, through the skin (percutaneous), or internal jugular vein (transjugular).[87] Endoscopic ultrasound-guided liver biopsy (EUS), using the percutaneous or transjugular route, has become a good alternative to use.[88] EUS can target liver areas that are widely separated,[89] and can deliver bi-lobar biopsies. A biopsy is not necessary if the clinical, laboratory, and radiologic data suggest cirrhosis. Furthermore, a small but significant risk of complications is associated with liver biopsy, and cirrhosis itself predisposes for complications caused by liver biopsy.[90]

Once the biopsy is obtained, a pathologist will study the sample. Cirrhosis is defined by its features on microscopy: (1) the presence of regenerating nodules of hepatocytes and (2) the presence of fibrosis, or the deposition of connective tissue between these nodules. The pattern of fibrosis seen can depend on the underlying insult that led to cirrhosis. Fibrosis can also proliferate even if the underlying process that caused it has resolved or ceased. The fibrosis in cirrhosis can lead to destruction of other normal tissues in the liver: including the sinusoids, the space of Disse, and other vascular structures, which leads to altered resistance to blood flow in the liver, and portal hypertension.[91]

As cirrhosis can be caused by many different entities which injure the liver in different ways, cause-specific abnormalities may be seen. For example, in chronic hepatitis B, there is infiltration of the liver parenchyma with lymphocytes. In congestive hepatopathy there are erythrocytes and a greater amount of fibrosis in the tissue surrounding the hepatic veins.[92] In primary biliary cholangitis, there is fibrosis around the bile duct, the presence of granulomas and pooling of bile.[93] Lastly in alcoholic cirrhosis, there is infiltration of the liver with neutrophils.

Macroscopically, the liver is initially enlarged, but with the progression of the disease, it becomes smaller. Its surface is irregular, the consistency is firm, and if associated with steatosis the color is yellow. Depending on the size of the nodules, there are three macroscopic types: micronodular, macronodular, and mixed cirrhosis. In the micronodular form (Laennec's cirrhosis or portal cirrhosis), regenerating nodules are under 3 mm. In macronodular cirrhosis (post-necrotic cirrhosis), the nodules are larger than 3 mm. Mixed cirrhosis consists of nodules of different sizes.[94]

Grading

The severity of cirrhosis is commonly classified with the Child–Pugh score (also known as the Child–Pugh–Turcotte score).[95] This system was devised in 1964 by Child and Turcotte, and modified in 1973 by Pugh and others.[96] It was first established to determine who would benefit from elective surgery for portal decompression. This scoring system uses multiple lab values including bilirubin, albumin, and INR. The presence of ascites and severity of encephalopathy is also included in the scoring. The classification system includes class A, B, or C.[97] Class A has a favorable prognosis while class C is at high risk of death.

Child-Pugh Score in Relation to Liver Function, Prognosis and Post-op Mortality!Child-Pugh Class!Points!Liver Function!Prognosis!Abdominal surgery post-operative mortality
Child-Pugh Class A5–6 pointsGood liver function15–20 years10%
Child-Pugh Class B7–9 pointsModerately impaired liver function30%
Child-Pugh Class C10–15 pointsAdvanced liver dysfunction1–3 years82%
The Child-Pugh score is a validated predictor of mortality after a major surgery. For example, Child class A patients have a 10% mortality rate and Child class B patients have a 30% mortality rate while Child class C patients have a 70–80% mortality rate after abdominal surgery. Elective surgery is usually reserved for those in Child class A patients. There is an increased risk for Child class B individuals and they may require medical optimization. Overall, it is not recommended for Child class C patients to undergo elective surgery.

In the past, the Child-Pugh classification was used to determine people who were candidates for a liver transplant. Child-Pugh class B is usually an indication for evaluation for transplant. However, there were many issues when applying this score to liver transplant eligibility. Thus, the MELD score was created.

The Model for End-Stage Liver Disease (MELD) score was later developed and approved in 2002.[98] It was approved by the United Network for Organ Sharing (UNOS) as a way to determine the allocation of liver transplants to awaiting people in the United States.[99] It is also used as a validated survival predictor of cirrhosis, alcoholic hepatitis, acute liver failure, and acute hepatitis.[100] The variables included bilirubin, INR, creatinine, and dialysis frequency. In 2016, sodium was added to the variables and the score is often referred to as MELD-Na.[101]

MELD-Plus is a further risk score to assess severity of chronic liver disease. It was developed in 2017 as a result of a collaboration between Massachusetts General Hospital and IBM.[102] Nine variables were identified as effective predictors for 90-day mortality after a discharge from a cirrhosis-related hospital admission. The variables include all Model for End-Stage Liver Disease (MELD)'s components, as well as sodium, albumin, total cholesterol, white blood cell count, age, and length of stay.

The hepatic venous pressure gradient (difference in venous pressure between incoming and outgoing blood to the liver) also determines the severity of cirrhosis, although it is hard to measure. A value of 16 mm or more means a greatly increased risk of death.[103]

Prevention

Key prevention strategies for cirrhosis are population-wide interventions to reduce alcohol intake (through pricing strategies, public health campaigns, and personal counseling), programs to reduce the transmission of viral hepatitis, and screening of relatives of people with hereditary liver diseases.[104]

Little is known about factors affecting cirrhosis risk and progression. However, many studies have provided increasing evidence for the protective effects of coffee consumption against the progression of liver disease. These effects are more noticeable in liver disease that is associated with alcohol use disorder. Coffee has antioxidant and antifibrotic effects. Caffeine may not be the important component; polyphenols may be more important. Drinking two or more cups of coffee a day is associated with improvements in the liver enzymes ALT, AST, and GGT. Even in those with liver disease, coffee consumption can lower fibrosis and cirrhosis.[105]

Treatment

Generally, liver damage from cirrhosis cannot be reversed, but treatment can stop or delay further progression and reduce complications. A healthy diet is encouraged, as cirrhosis may be an energy-consuming process. A recommended diet consists of high-protein, high-fiber diet plus supplementation with branched-chain amino acids.[106] Close follow-up is often necessary. Antibiotics are prescribed for infections, and various medications can help with itching. Laxatives, such as lactulose, decrease the risk of constipation. Carvedilol increases survival benefit for people with cirrhosis and portal hypertension.[107] Diuretics in combination with low salt diet reduce fluid in body which helps reduce oedema.[108]

Alcoholic cirrhosis caused by alcohol use disorder is treated by abstaining from alcohol. Treatment for hepatitis-related cirrhosis involves medications used to treat the different types of hepatitis, such as interferon for viral hepatitis and corticosteroids for autoimmune hepatitis.

Cirrhosis caused by Wilson's disease is treated by removing the copper which builds up in organs. This is carried out using chelation therapy such as penicillamine. When the cause is an iron overload, iron is removed using a chelation agent such as deferoxamine or by bloodletting.

As of 2021, there are recent studies studying drugs to prevent cirrhosis caused by non-alcoholic fatty liver disease (NAFLD or NASH). A drug called semaglutide was shown to provide greater NASH resolution versus placebo. No improvement in fibrosis was observed.[109] A combination of cilofexor/firsocostat was studied in people with bridging fibrosis and cirrhosis. It was observed to have led to improvements in NASH activity with a potential antifibrotic effect.[110] Lanifibranor is also shown to prevent worsening fibrosis.[111]

Preventing further liver damage

Regardless of the underlying cause of cirrhosis, consumption of alcohol and other potentially damaging substances is discouraged. There is no evidence that supports the avoidance or dose reduction of paracetamol in people with compensated cirrhosis; it is thus considered a safe analgesic for said individuals.[112]

Vaccination against hepatitis A and hepatitis B is recommended early in the course of illness due to decline in effectiveness of the vaccines with decompensation.[113]

Treating the cause of cirrhosis prevents further damage; for example, giving oral antivirals such as entecavir and tenofovir where cirrhosis is due to hepatitis B prevents progression of cirrhosis. Similarly, control of weight and diabetes prevents deterioration in cirrhosis due to non-alcoholic fatty liver disease.[114]

People with cirrhosis or liver damage are often advised to avoid drugs that could further harm the liver. These include several drugs such as anti-depressants, certain antibiotics, and NSAIDs (like ibuprofen).[115] These agents are hepatotoxic as they are metabolized by the liver. If a medication that harms the liver is still recommended by a doctor, the dosage can be adjusted to aim for minimal stress on the liver.

Lifestyle

According to a 2018 systematic review based on studies that implemented 8 to 14 week-long exercise programs, there is currently insufficient scientific evidence regarding either the beneficial or harmful effects of physical exercise in people with cirrhosis on all-cause mortality, morbidity (including both serious and non-serious adverse events), health-related quality of life, exercise capacity and anthropomorphic measures.[116] These conclusions were based on low to very low quality research, which imposes the need to develop further research with higher quality, especially to evaluate its effects on clinical outcomes.

Transplantation

See main article: Liver transplantation. If complications cannot be controlled or when the liver ceases functioning, liver transplantation is necessary. Survival from liver transplantation has been improving over the 1990s, and the five-year survival rate is now around 80%. The survival rate depends largely on the severity of disease and other medical risk factors in the recipient.[117] In the United States, the MELD score is used to prioritize patients for transplantation.[118] Transplantation necessitates the use of immune suppressants (ciclosporin or tacrolimus).

Decompensated cirrhosis

Manifestations of decompensation in cirrhosis include gastrointestinal bleeding, hepatic encephalopathy, jaundice or ascites. In patients with previously stable cirrhosis, decompensation may occur due to various causes, such as constipation, infection (of any source), increased alcohol intake, medication, bleeding from esophageal varices or dehydration. It may take the form of any of the complications of cirrhosis listed below.

People with decompensated cirrhosis generally require admission to a hospital, with close monitoring of the fluid balance, mental status, and emphasis on adequate nutrition and medical treatment – often with diuretics, antibiotics, laxatives or enemas, thiamine and occasionally steroids, acetylcysteine and pentoxifylline.[119] Administration of saline is avoided, as it would add to the already high total body sodium content that typically occurs in cirrhosis. Life expectancy without liver transplant is low, at most three years.

Palliative care

Palliative care is specialized medical care that focuses on providing patients with relief from the symptoms, pain, and stress of a serious illness, such as cirrhosis. The goal of palliative care is to improve quality of life for both the patient and the patient's family and it is appropriate at any stage and for any type of cirrhosis.[120]

Especially in the later stages, people with cirrhosis experience significant symptoms such as abdominal swelling, itching, leg edema, and chronic abdominal pain which would be amenable for treatment through palliative care.[121] Because the disease is not curable without a transplant, palliative care can also help with discussions regarding the person's wishes concerning health care power of attorney, do not resuscitate decisions and life support, and potentially hospice.[121] Despite proven benefit, people with cirrhosis are rarely referred to palliative care.[122]

Immunity

Cirrhosis is known to cause immune dysfunction in numerous ways. It impedes the immune system from working normally.

Bleeding and blood clot risk

Cirrhosis can increase the risk of bleeding. The liver produces various proteins in the coagulation cascade (coagulation factors II, VII, IX, X, V, and VI). When damaged, the liver is impaired in its production of these proteins.[123] This will ultimately increase bleeding as clotting factors are diminished. Clotting function is estimated by lab values, mainly platelet count, prothrombin time (PT), and international normalized ratio (INR).

The American Gastroenterological Association (AGA) provided recommendations in 2021 in regards to coagulopathy management of cirrhotic patients in certain scenarios.

Complications

Ascites

Salt restriction is often necessary, as cirrhosis leads to accumulation of salt (sodium retention). Diuretics may be necessary to suppress ascites. Diuretic options for inpatient treatment include aldosterone antagonists (spironolactone) and loop diuretics. Aldosterone antagonists are preferred for people who can take oral medications and are not in need of an urgent volume reduction. Loop diuretics can be added as additional therapy.[124]

Where salt restriction and the use of diuretics are ineffective then paracentesis may be the preferred option.[125] This procedure requires the insertion of a plastic tube into the peritoneal cavity. Human serum albumin solution is usually given to prevent complications from the rapid volume reduction. In addition to being more rapid than diuretics, 4–5 liters of paracentesis is more successful in comparison to diuretic therapy.[124]

Esophageal and gastric variceal bleeding

For portal hypertension, nonselective beta blockers such as propranolol or nadolol are commonly used to lower blood pressure over the portal system. In severe complications from portal hypertension, transjugular intrahepatic portosystemic shunting (TIPS) is occasionally indicated to relieve pressure on the portal vein. As this shunting can worsen hepatic encephalopathy, it is reserved for those patients at low risk of encephalopathy. TIPS is generally regarded only as a bridge to liver transplantation[126] or as a palliative measure. Balloon-occluded retrograde transvenous obliteration can be used to treat gastric variceal bleeding.[127]

Gastroscopy (endoscopic examination of the esophagus, stomach, and duodenum) is performed in cases of established cirrhosis. If esophageal varices are found, prophylactic local therapy may be applied such as sclerotherapy or banding, and beta blockers may be used.[128] [129] [130]

Hepatic encephalopathy

Hepatic encephalopathy is a potential complication of cirrhosis. It may lead to functional neurological impairment ranging from mild confusion to coma. Hepatic encephalopathy is primarily caused by the accumulation of ammonia in the blood, which causes neurotoxicity when crossing the blood-brain barrier. Ammonia is normally metabolized by the liver; as cirrhosis causes both decreased liver function and increased portosystemic shunting (allowing blood to bypass the liver), systemic ammonia levels gradually rise and lead to encephalopathy.[131]

Most pharmaceutical approaches to treating hepatic encephalopathy focus on reducing ammonia levels.[132] Per 2014 guidelines,[133] the first-line treatment involves the use of lactulose, a non-absorbable disaccharide which decreases the pH level of the colon when it is metabolized by intestinal bacteria. The lower colonic pH causes increased conversion of ammonia into ammonium, which is then excreted from the body.[134] Rifaximin, an antibiotic that inhibits the function of ammonia-producing bacteria in the gastrointestinal tract,[135] is recommended for use in combination with lactulose as prophylaxis against recurrent episodes of hepatic encephalopathy.[136] [137]

In addition to pharmacotherapy, providing proper hydration and nutritional support is also essential. Appropriate quantities of protein uptake is encouraged.[138] Several factors may precipitate hepatic encephalopathy, which include alcohol use, excess protein, gastrointestinal bleeding, infection, constipation, and vomiting/diarrhea. Drugs such as benzodiazepines, diuretics, or narcotics can also precipitate encephalopathic events. A low protein diet is recommended with gastrointestinal bleeding.

The severity of hepatic encephalopathy is determined by assessing the patient's mental status. This is generally a subjective assessment, although several attempts at creating criteria to help standardize this assessment have been published. One example is the West Haven criteria, reproduced below.

Grade
Mental status
Grade 1: MildChanges in behavior
Mild confusion
Slurred speech
Disordered sleep
Grade 2: ModerateLethargy
Moderate confusion
Grade 3: SevereStupor
Incoherent
Sleeping but arousable
Grade 4: ComaComa/Unresponsive

Hepatorenal syndrome

Hepatorenal syndrome is a serious complication of end-stage cirrhosis when kidney damage is also involved.[139]

Spontaneous bacterial peritonitis

People with ascites due to cirrhosis are at risk of spontaneous bacterial peritonitis.

Portal hypertensive gastropathy

Portal hypertensive gastropathy refers to changes in the mucosa of the stomach in people with portal hypertension, and is associated with cirrhosis severity.[140]

Infection

Cirrhosis can cause immune system dysfunction, leading to infection. Signs and symptoms of infection may be nonspecific and are more difficult to recognize (for example, worsening encephalopathy but no fever).[141] Moreover, infections in cirrhosis are major triggers for other complications (ascites, variceal bleeding, hepatic encephalopathy, organ failures, death).

Hepatocellular carcinoma

Hepatocellular carcinoma is the most common primary liver cancer, and the most common cause of death in people with cirrhosis.[142] Screening using an MRI scan can detect this cancer and is often carried out for early signs which has been shown to improve outcomes.[1] [143]

Epidemiology

Each year, approximately one million deaths are due to complications of cirrhosis, making cirrhosis the 11th most common cause of death globally.[144] Cirrhosis and chronic liver disease were the tenth leading cause of death for men and the twelfth for women in the United States in 2001, killing about 27,000 people each year.[145]

The cause of cirrhosis can vary; alcohol and non-alcoholic fatty liver disease are main causes in western and industrialized countries, whereas viral hepatitis is the predominant cause in low and middle-income countries. Cirrhosis is more common in men than in women.[146] The cost of cirrhosis in terms of human suffering, hospital costs, and lost productivity is high.

Globally, age-standardized disability-adjusted life year (DALY) rates have decreased from 1990 to 2017, with the values going from 656.4 years per 100,000 people to 510.7 years per 100,000 people.[147] In males DALY rates have decreased from 903.1 years per 100,000 population in 1990, to 719.3 years per 100,000 population in 2017; in females the DALY rates have decreased from 415.5 years per 100,000 population in 1990, to 307.6 years per 100,000 population in 2017. However, globally the total number of DALYs have increased by 10.9 million from 1990 to 2017, reaching the value of 41.4 million DALYs.[147]

Etymology

The word "cirrhosis" is a neologism derived from κίρρωσις; kirrhos Greek, Ancient (to 1453);: κιρρός, meaning "yellowish, tawny" (the orange yellow colour of the diseased liver) and the suffix -osis, i.e. "condition" in medical terminology.[148] While the clinical entity was known before, René Laennec gave it this name in an 1819 paper.[25]

See also

External links

Notes and References

  1. Book: Ferri FF . Ferri's clinical advisor 2019 : 5 books in 1 . 2019 . Philadelphia, PA . 978-0-323-53042-2 . 337–339.
  2. Web site: Treatment for Cirrhosis NIDDK . National Institute of Diabetes and Digestive and Kidney Diseases . 6 March 2021 . 20 March 2021 . https://web.archive.org/web/20210320212702/https://www.niddk.nih.gov/health-information/liver-disease/cirrhosis/treatment . live .
  3. Web site: Cirrhosis . 29 June 2020 . nhs.uk . 16 July 2024. live . 5 October 2017 . https://web.archive.org/web/20171005102913/http://www.nhs.uk/conditions/cirrhosis/pages/introduction.aspx.
  4. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. The Lancet. 2014. 383. 9930. 1749–1761. 10.1016/S0140-6736(14)60121-5. 24480518.
  5. Book: Sharma B, John S. 31 October 2022. Hepatic Cirrhosis. StatPearls [Internet]]. StatPearls Publishing. Treasure Island, Florida. National Library of Medicine. 16 July 2024. 29494026. Bookshelf ID NBK482419.
  6. Book: Sherlock's diseases of the liver and biliary system . Dooley JS, Lok AS, Garcia-Tsao G, Pinzani M . 8 June 2018 . 978-1-119-23756-3 . 13th . Hoboken, New Jersey. Wiley Blackwell. 82–92. 1019837000. Chapter 6: Hepatic Fibrinogenesis. Bansal MB, Friedman SL.
  7. Haep N, Florentino RM, Squires JE, Bell A, Soto-Gutierrez A. The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone. Seminars in Liver Disease. 41. 2. 213–224. 2021. 10.1055/s-0041-1725023. 33992030. 8996333.
  8. Book: McCormick PA, Jalan R. Chapter 8: Hepatic Cirrhosis. Sherlock's diseases of the liver and biliary system . Dooley JS, Lok AS, Garcia-Tsao G, Pinzani M. 107–126. 8 June 2018 . 978-1-119-23756-3 . 13th . Hoboken, New Jersey. Wiley Blackwell. 1019837000.
  9. Web site: Symptoms & Causes of Cirrhosis NIDDK . National Institute of Diabetes and Digestive and Kidney Diseases . 8 February 2021 . 8 February 2021 . https://web.archive.org/web/20210208112830/https://www.niddk.nih.gov/health-information/liver-disease/cirrhosis/symptoms-causes . live .
  10. Web site: Definition & Facts for Cirrhosis NIDDK . National Institute of Diabetes and Digestive and Kidney Diseases . 2021-03-10 . 2021-03-11 . https://web.archive.org/web/20210311155052/https://www.niddk.nih.gov/health-information/liver-disease/cirrhosis/definition-facts . live .
  11. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN, ((NAFLD Nomenclature consensus group)). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Annals of Hepatology. 29. 1. 2024. Art. No. 101133. 10.1016/j.aohep.2023.101133. free. 37364816. 2434/1050088. free.
  12. Castera L, Friedrich-Rust M, Loomba R . Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease . Gastroenterology . 156 . 5 . 1264–1281.e4 . April 2019 . 30660725 . 7505052 . 10.1053/j.gastro.2018.12.036 .
  13. News: Ultrastructural Changes In The Liver Of Intravenous Heroin Addiction. Journal of the Association of Basic Medical Sciences. February 2010. 5596609 . Ilić . G. . Karadžić . R. . Kostić-Banović . L. . Stojanović . J. . Antović . A. . Bosnian Journal of Basic Medical Sciences . 10 . 1 . 36–43 .
  14. Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, etal . Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 . Lancet . 385 . 9963 . 117–171 . January 2015 . 25530442 . 4340604 . 10.1016/S0140-6736(14)61682-2 . GBD 2013 Mortality Causes of Death Collaborators .
  15. Web site: Alcoholic liver disease . MedlinePlus Medical Encyclopedia . 2021-03-10 . live . 2019-05-27 . https://web.archive.org/web/20190527141122/https://medlineplus.gov/ency/article/000281.htm .
  16. News: Heroin and Liver Damage. Banyan Medical Centers. August 7, 2022.
  17. Web site: Definition & Facts of NAFLD & NASH NIDDK . National Institute of Diabetes and Digestive and Kidney Diseases . 9 March 2021 . 12 March 2021 . https://web.archive.org/web/20210312180930/https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/definition-facts . live .
  18. Web site: Cirrhosis . 19 May 2015 . April 23, 2014 . National Institute of Diabetes and Digestive and Kidney Diseases . live . https://web.archive.org/web/20150609090212/http://www.niddk.nih.gov/health-information/health-topics/liver-disease/cirrhosis/Pages/facts.aspx . 9 June 2015.
  19. Web site: Back to Basics: Outpatient Management of Cirrhosis. Grady. John. Liver Fellow Network. American Association for the Study of Liver Diseases. 16 July 2024. 15 February 2024.
  20. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, Mendiratta-Lala M, Brown DB, Rilling WS, Goyal L, Wei AC, Taddei TH. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. 2023. Hepatology. 78. 6. 1922–1965. 10.1097/HEP.0000000000000466. 37199193. 10663390 . December 1, 2024 .
  21. Liao Z, Tang C, Luo R, Gu X, Zhou J, Gao J. 2023. Current Concepts of Precancerous Lesions of Hepatocellular Carcinoma: Recent Progress in Diagnosis. Diagnostics. 13. 7. 1211 . Art. No. 1211. 10.3390/diagnostics13071211. free. 37046429. 10093043.
  22. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 . Lancet . 388 . 10053 . 1545–1602 . October 2016 . 27733282 . 5055577 . 10.1016/S0140-6736(16)31678-6 . Vos . Theo . Allen . Christine . Arora . Megha . Barber . Ryan M. . Bhutta . Zulfiqar A. . Brown . Alexandria . Carter . Austin . Casey . Daniel C. . Charlson . Fiona J. . Chen . Alan Z. . Coggeshall . Megan . Cornaby . Leslie . Dandona . Lalit . Dicker . Daniel J. . Dilegge . Tina . Erskine . Holly E. . Ferrari . Alize J. . Fitzmaurice . Christina . Fleming . Tom . Forouzanfar . Mohammad H. . Fullman . Nancy . Gething . Peter W. . Goldberg . Ellen M. . Graetz . Nicholas . Haagsma . Juanita A. . Hay . Simon I. . Johnson . Catherine O. . Kassebaum . Nicholas J. . Kawashima . Toana . Kemmer . Laura .
  23. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, etal . GBD 2015 Mortality and Causes of Death Collaborators . Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015 . Lancet . 388 . 10053 . 1459–1544 . October 2016 . 27733281 . 5388903 . 10.1016/s0140-6736(16)31012-1 .
  24. Book: Brower ST . Elective general surgery : an evidence-based approach . 2012 . McGraw-Hill Medical . New York . 978-1-60795-109-4 . 36 . live . https://web.archive.org/web/20170908175353/https://books.google.com/books?id=ctqtT0hieL0C&pg=PA366 . 2017-09-08.
  25. Roguin A . Rene Theophile Hyacinthe Laënnec (1781-1826): the man behind the stethoscope . Clinical Medicine & Research . 4 . 3 . 230–235 . September 2006 . 17048358 . 1570491 . 10.3121/cmr.4.3.230 .
  26. Web site: 2024 . Cirrhosis of the liver . cleveland clinic.
  27. 2024 . Steatorrhea in patients with liver disease . 1931370 . Canadian Medical Association Journal . 105 . 11 . 1143–1154 . 5150072 . Williams CN, Sidorov JJ .
  28. Book: Samant H, Kothadia JP . Spider Angioma . 2022 . http://www.ncbi.nlm.nih.gov/books/NBK507818/ . StatPearls . Treasure Island (FL) . StatPearls Publishing . 29939595 . 2022-03-14 .
  29. Kur P, Kolasa-Wołosiuk A, Misiakiewicz-Has K, Wiszniewska B . Sex Hormone-Dependent Physiology and Diseases of Liver . International Journal of Environmental Research and Public Health . 17 . 8 . E2620 . April 2020 . 32290381 . 7216036 . 10.3390/ijerph17082620 . free .
  30. Serrao R, Zirwas M, English JC . Palmar erythema . American Journal of Clinical Dermatology . 8 . 6 . 347–56 . 2007 . 18039017 . 10.2165/00128071-200708060-00004 . 33297418 .
  31. Book: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Swerdloff RS, Ng CM . Gynecomastia: Etiology, Diagnosis, and Treatment . 2000 . http://www.ncbi.nlm.nih.gov/books/NBK279105/ . Endotext . Feingold KR, Anawalt B, Boyce A, Chrousos G . South Dartmouth (MA) . MDText.com, Inc. . 25905330 . 2022-03-16 .
  32. Book: Harrison's principles of internal medicine. . McGraw-Hill . 2012 . 978-0-07-174889-6 . Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J . 18th . New York . Chapter 308. Cirrhosis and Its Complications.
  33. Book: Kim SM, Yalamanchi S, Dobs AS . Male Hypogonadism and Liver Disease . 2017 . Male Hypogonadism . 219–234 . Winters SJ, Huhtaniemi IT . Cham . Springer International Publishing . 10.1007/978-3-319-53298-1_11 . 978-3-319-53296-7 .
  34. Qi X, An S, Li H, Guo X . 2017-08-24 . Recurrent scrotal edema in liver cirrhosis . AME Medical Journal . 2 . 124 . 10.21037/amj.2017.08.22 . free .
  35. Plauth M, Schütz ET . September 2002 . Cachexia in liver cirrhosis . International Journal of Cardiology . 85 . 1 . 83–87 . 10.1016/s0167-5273(02)00236-x . 12163212.
  36. Web site: Jeffrey G . 7 October 2021 . Cirrhosis of the Liver . emedicinehealth . 15 March 2022.
  37. Web site: Jaundice - Hepatic and Biliary Disorders . 2022-03-16 . Merck Manuals Professional Edition.
  38. Web site: Portal Hypertension . 2022-03-16 . www.hopkinsmedicine.org.
  39. Book: Meseeha M, Attia M . Esophageal Varices . 2022 . http://www.ncbi.nlm.nih.gov/books/NBK448078/ . StatPearls . Treasure Island (FL) . StatPearls Publishing . 28846255 . 2022-03-16 .
  40. Masoodi I, Farooq O, Singh R, Ahmad N, Bhat M, Wani A . Courveilhier baumgarten syndrome: a rare syndrome revisited . International Journal of Health Sciences . 3 . 1 . 97–99 . January 2009 . 21475517 . 3068787 .
  41. Witkowska AB, Jasterzbski TJ, Schwartz RA . Terry's Nails: A Sign of Systemic Disease . Indian Journal of Dermatology . 62 . 3 . 309–311 . 2017 . 28584375 . 5448267 . 10.4103/ijd.IJD_98_17 . free.
  42. Abd El Meged MM . 2019-04-01 . Patterns of nail changes in chronic liver diseases . Sohag Medical Journal . 23 . 2 . 166–170 . 10.21608/smj.2019.47672 . 203813520 . 1687-8353. free .
  43. Book: Friedman L . Handbook of Liver Disease, 4e . Elsevier . 2018 . 978-0-323-47874-8.
  44. Web site: Brennan D . What Is Fetor Hepaticus? . 2022-03-17 . WebMD.
  45. Samji NS, Buggs AM, Roy PK . Medscape . WebMD LLC. . 2021-10-17 . Anand BS . Viral Hepatitis: Background, Pathophysiology, Etiology .
  46. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP . The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide . Journal of Hepatology . 45 . 4 . 529–538 . October 2006 . 16879891 . 10.1016/j.jhep.2006.05.013 .
  47. Web site: Cirrhosis of the Liver . 2022-03-17 . American Liver Foundation.
  48. Stickel F, Datz C, Hampe J, Bataller R . Pathophysiology and Management of Alcoholic Liver Disease: Update 2016 . Gut and Liver . 11 . 2 . 173–188 . March 2017 . 28274107 . 5347641 . 10.5009/gnl16477 .
  49. Book: Current medical diagnosis and treatment 2014. . Friedman LS . Mcgraw-Hill . 2014 . 978-0-07-180633-6 . [S.l.] . Chapter 16. Liver, Biliary Tract, & Pancreas Disorders.
  50. Book: Machado MV, Diehl AM . Pathogenesis of Nonalcoholic Fatty Liver Disease . 369–390 . Sanyal AJ, Boyer TD, Terrault NA, Lindor KD . 2018 . Zakim and Boyer's Hepatology . 10.1016/c2013-0-19055-1. 978-0-323-37591-7 .
  51. Golabi P, Paik JM, Arshad T, Younossi Y, Mishra A, Younossi ZM . Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities . Hepatology Communications . 4 . 8 . 1136–1148 . August 2020 . 32766474 . 7395070 . 10.1002/hep4.1534 .
  52. Web site: Diagnosis of NAFLD & NASH NIDDK . National Institute of Diabetes and Digestive and Kidney Diseases . 9 March 2021 . 4 March 2021 . https://web.archive.org/web/20210304223353/https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/diagnosis . live .
  53. News: Heroin Addiction Health Conditions. Bedrock Recovery Center. August 7, 2022.
  54. Web site: Primary Biliary Cholangitis: Symptoms, Causes, Treatments . 2022-03-17 . Cleveland Clinic.
  55. Book: Coenen IC, Houwen RH . Indian childhood cirrhosis and other disorders of copper handling. . Clinical and Translational Perspectives on Wiloson Disease . January 2019 . 449–453 . Academic Press . 10.1016/B978-0-12-810532-0.00044-6 . 978-0-12-810532-0 . 80994882 .
  56. Web site: Oiseth S, Jones L, Maza E . Galactosemia . The Lecturio Medical Concept Library . 15 August 2021.
  57. Book: Hammer GD, McPhee SJ . Pathophysiology of disease : an introduction to clinical medicine . 2010 . McGraw-Hill Medical . New York . 978-0-07-162167-0 . Chapter 14: Liver Disease. Cirrhosis . 6th.
  58. Hassan S, Shah H, Shawana S . Dysregulated epidermal growth factor and tumor growth factor-beta receptor signaling through GFAP-ACTA2 protein interaction in liver fibrosis . Pakistan Journal of Medical Sciences . 36 . 4 . 782–787 . 2020 . 32494274 . 7260937 . 10.12669/pjms.36.4.1845 .
  59. Iredale JP . Cirrhosis: new research provides a basis for rational and targeted treatments . BMJ . 327 . 7407 . 143–147 . July 2003 . 12869458 . 1126509 . 10.1136/bmj.327.7407.143 . live . https://web.archive.org/web/20041029175310/http://bmj.bmjjournals.com/cgi/content/full/327/7407/143 . 2004-10-29 .
  60. Puche JE, Saiman Y, Friedman SL . Hepatic stellate cells and liver fibrosis . Comprehensive Physiology . 3 . 4 . 1473–1492 . October 2013 . 24265236 . 10.1002/cphy.c120035 . 978-0-470-65071-4 .
  61. Wu M, Sharma PG, Grajo JR . The Echogenic Liver: Steatosis and Beyond . Ultrasound Quarterly . 37 . 4 . 308–314 . September 2020 . 32956242 . 10.1097/RUQ.0000000000000510 . 221842327 .
  62. Yeom SK, Lee CH, Cha SH, Park CM . Prediction of liver cirrhosis, using diagnostic imaging tools . World Journal of Hepatology . 7 . 17 . 2069–2079 . August 2015 . 26301049 . 4539400 . 10.4254/wjh.v7.i17.2069 . free .
  63. Chapman J, Goyal A, Azevedo AM. Splenomegaly. [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430907/
  64. Berzigotti A, Seijo S, Reverter E, Bosch J . Assessing portal hypertension in liver diseases . Expert Review of Gastroenterology & Hepatology . 7 . 2 . 141–155 . February 2013 . 23363263 . 10.1586/egh.12.83 . 31057915 . free .
  65. Iranpour P, Lall C, Houshyar R, Helmy M, Yang A, Choi JI, Ward G, Goodwin SC . January 2016 . Altered Doppler flow patterns in cirrhosis patients: an overview . Ultrasonography . 35 . 1 . 3–12 . 10.14366/usg.15020 . 4701371 . 26169079.
  66. Goncalvesova E, Varga I, Tavacova M, Lesny P . Changes of portal vein flow in heart failure patients with liver congestion . European Heart Journal . 34 . suppl 1 . 2013 . 627 . 0195-668X . 10.1093/eurheartj/eht307.P627. free.
  67. Book: Dietrich CF . Ultrasonography . https://books.google.com/books?id=ZfJN6NS0ZY4C&pg=PA367 . 367 . https://web.archive.org/web/20181130030356/https://books.google.se/books?id=ZfJN6NS0ZY4C&pg=PA367 . 2018-11-30 . Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases . 1 . Dancygier H . Springer Science & Business Media . 2009 . 978-3-540-93842-2.
  68. Web site: Elastography: MedlinePlus Medical Test . 2022-03-21 . medlineplus.gov.
  69. Barr RG, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-Tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D, Levine D . Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement . Radiology . 276 . 3 . 845–861 . September 2015 . 26079489 . 10.1148/radiol.2015150619 .
  70. Srinivasa Babu A, Wells ML, Teytelboym OM, Mackey JE, Miller FH, Yeh BM, Ehman RL, Venkatesh SK . Elastography in Chronic Liver Disease: Modalities, Techniques, Limitations, and Future Directions . Radiographics . 36 . 7 . 1987–2006 . 2016-11-01 . 27689833 . 5584553 . 10.1148/rg.2016160042 .
  71. Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, Adhoute X, Bertet J, Couzigou P, de Lédinghen V . Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study . Gut . 55 . 3 . 403–408 . March 2006 . 16020491 . 1856085 . 10.1136/gut.2005.069153 .
  72. Pavlov CS, Casazza G, Nikolova D, Tsochatzis E, Burroughs AK, Ivashkin VT, Gluud C . Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease . The Cochrane Database of Systematic Reviews . 1 . CD010542 . January 2015 . 1 . 25612182 . 7081746 . 10.1002/14651858.cd010542.pub2 .
  73. Udell JA, Wang CS, Tinmouth J, FitzGerald JM, Ayas NT, Simel DL, Schulzer M, Mak E, Yoshida EM . February 2012 . Does this patient with liver disease have cirrhosis? . JAMA . 307 . 8 . 832–842 . 10.1001/jama.2012.186 . 22357834.
  74. Gudowska M, Gruszewska E, Panasiuk A, Cylwik B, Świderska M, Flisiak R, Szmitkowski M, Chrostek L . February 2016 . Selected Noninvasive Markers in Diagnosing Liver Diseases . Laboratory Medicine . 47 . 1 . 67–72 . 10.1093/labmed/lmv015 . 26715612 . free.
  75. Book: Schiff's diseases of the liver. . John Wiley & Sons . 1999 . 978-0-470-65468-2 . Maddrey WC, Schiff ER, Sorrell MF . 11th . Chichester, West Sussex, UK . Evaluation of the Liver A: Laboratory Test.
  76. Book: Current practice guidelines in primary care 2013 . Slater JS, Esherick DS, Clark ED . 2012-12-18 . McGraw-Hill Medical . 978-0-07-179750-4 . New York . Chapter 3: Disease Management.
  77. Van Thiel DH, Gavaler JS, Schade RR . February 1985 . Liver disease and the hypothalamic pituitary gonadal axis . Seminars in Liver Disease . 5 . 1 . 35–45 . 10.1055/s-2008-1041756 . 3983651. 35436861 .
  78. Halfon P, Munteanu M, Poynard T . September 2008 . FibroTest-ActiTest as a non-invasive marker of liver fibrosis . Gastroenterologie Clinique et Biologique . 32 . 6 Suppl 1 . 22–39 . 10.1016/S0399-8320(08)73991-5 . 18973844.
  79. Tornai D, Antal-Szalmas P, Tornai T, Papp M, Tornai I, Sipeki N, Janka T, Balogh B, Vitalis Z . March 2021 . Abnormal ferritin levels predict development of poor outcomes in cirrhotic outpatients: a cohort study . BMC Gastroenterology . 21 . 1 . 94 . 10.1186/s12876-021-01669-w . 7923668 . 33653274 . free .
  80. Maiwall R, Kumar S, Chaudhary AK, Maras J, Wani Z, Kumar C, Rastogi A, Bihari C, Vashisht C, Sarin SK . July 2014 . Serum ferritin predicts early mortality in patients with decompensated cirrhosis . Journal of Hepatology . 61 . 1 . 43–50 . 10.1016/j.jhep.2014.03.027 . 24681346.
  81. Papp M, Vitalis Z, Altorjay I, Tornai I, Udvardy M, Harsfalvi J, Vida A, Kappelmayer J, Lakatos PL, Antal-Szalmas P . April 2012 . Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections . live . Liver International . 32 . 4 . 603–611 . 10.1111/j.1478-3231.2011.02689.x . 22145664 . https://web.archive.org/web/20210425103201/https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1478-3231.2011.02689.x . 2021-04-25 . 2021-04-25 . 10326820.
  82. Papp M, Tornai T, Vitalis Z, Tornai I, Tornai D, Dinya T, Sumegi A, Antal-Szalmas P . November 2016 . Presepsin teardown - pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis . World Journal of Gastroenterology . 22 . 41 . 9172–9185 . 10.3748/wjg.v22.i41.9172 . 5107598 . 27895404 . free .
  83. Tornai T, Vitalis Z, Sipeki N, Dinya T, Tornai D, Antal-Szalmas P, Karanyi Z, Tornai I, Papp M . November 2016 . Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection . live . Liver International . 36 . 11 . 1628–1638 . 10.1111/liv.13133 . 27031405 . https://web.archive.org/web/20210425103201/https://onlinelibrary.wiley.com/doi/abs/10.1111/liv.13133 . 2021-04-25 . 2021-04-25 . free . 206174528 . 2437/223046.
  84. Laursen TL, Rødgaard-Hansen S, Møller HJ, Mortensen C, Karlsen S, Nielsen DT, Frevert S, Clemmesen JO, Møller S, Jensen JS, Bendtsen F, Grønbaek H . April 2017 . The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation . Liver International . 37 . 4 . 569–575 . 10.1111/liv.13262 . 27706896 . 46856702.
  85. Tornai D, Vitalis Z, Jonas A, Janka T, Foldi I, Tornai T, Sipeki N, Csillag A, Balogh B, Sumegi A, Foldesi R, Papp M, Antal-Szalmas P . September 2021 . Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality . Clinics and Research in Hepatology and Gastroenterology . 45 . 5 . 101579 . 10.1016/j.clinre.2020.11.009 . 33773436 . free.
  86. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, Guo J, Le Chatelier E, Yao J, Wu L, Zhou J, Ni S, Liu L, Pons N, Batto JM, Kennedy SP, Leonard P, Yuan C, Ding W, Chen Y, Hu X, Zheng B, Qian G, Xu W, Ehrlich SD, Zheng S, Li L . Alterations of the human gut microbiome in liver cirrhosis . Nature . 513 . 7516 . 59–64 . September 2014 . 25079328 . 10.1038/nature13568 . 2014Natur.513...59Q . 205239766 .
  87. McCarty TR, Bazarbashi AN, Njei B, Ryou M, Aslanian HR, Muniraj T . September 2020 . Endoscopic Ultrasound-Guided, Percutaneous, and Transjugular Liver Biopsy: A Comparative Systematic Review and Meta-Analysis . Clinical Endoscopy . 53 . 5 . 583–593 . 10.5946/ce.2019.211 . 7548145 . 33027584 . free.
  88. Mok SR, Diehl DL . January 2019 . The Role of EUS in Liver Biopsy . Current Gastroenterology Reports . 21 . 2 . 6 . 10.1007/s11894-019-0675-8 . 30706151 . 73440352.
  89. Diehl DL . April 2019 . Endoscopic Ultrasound-guided Liver Biopsy . Gastrointestinal Endoscopy Clinics of North America . 29 . 2 . 173–186 . 10.1016/j.giec.2018.11.002 . 6383155 . 30846147.
  90. Grant A, Neuberger J . October 1999 . Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology . live . Gut . 45 . Suppl 4 . IV1–IV11 . 10.1136/gut.45.2008.iv1 . 1766696 . 10485854 . https://web.archive.org/web/20070630073451/http://gut.bmj.com/cgi/content/full/45/suppl_4/IV1 . 2007-06-30 . The main cause of mortality after percutaneous liver biopsy is intraperitoneal haemorrhage as shown in a retrospective Italian study of 68,000 percutaneous liver biopsies, in which all six patients who died did so from intraperitoneal haemorrhage. Three of these patients had had a laparotomy, and all had either cirrhosis or malignant disease, both of which are risk factors for bleeding..
  91. Book: Brenner D, Rippe RA . Pathogenesis of Hepatic Fibrosis . Textbook of Gastroenterology . Yamada . Tadataka Yamada . 4th . 2 . 2003 . Lippincott Williams & Wilkins . 978-0-7817-2861-4.
  92. Giallourakis CC, Rosenberg PM, Friedman LS . The liver in heart failure . Clinics in Liver Disease . 6 . 4 . 947–67, viii–ix . November 2002 . 12516201 . 10.1016/S1089-3261(02)00056-9 .
  93. Heathcote EJ . Primary biliary cirrhosis: historical perspective . Clinics in Liver Disease . 7 . 4 . 735–740 . November 2003 . 14594128 . 10.1016/S1089-3261(03)00098-9 .
  94. Book: https://www.ncbi.nlm.nih.gov/books/NBK482419/ . Hepatic Cirrhosis . Bashar S, Savio J . StatPearls . StatPearls . 2020 . 29494026 . 2019-11-11 . https://web.archive.org/web/20200903005535/https://www.ncbi.nlm.nih.gov/books/NBK482419/ . 2020-09-03 . live.
  95. Book: Tsoris A, Marlar CA . Use Of The Child Pugh Score In Liver Disease . 2022 . StatPearls . Treasure Island (FL) . StatPearls Publishing . 31194448 . 2022-03-23 .
  96. Web site: Shakerdge K . What Are the MELD and Child-Pugh Scores for Liver Disease? . 2022-03-23 . WebMD.
  97. Web site: Child-Pugh Score for Cirrhosis Mortality . 2022-03-23 . MDCalc.
  98. Singal AK, Kamath PS . Model for End-stage Liver Disease . Journal of Clinical and Experimental Hepatology . 3 . 1 . 50–60 . March 2013 . 25755471 . 3940492 . 10.1016/j.jceh.2012.11.002 .
  99. Peng Y, Qi X, Guo X . Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies . Medicine . 95 . 8 . e2877 . February 2016 . 26937922 . 4779019 . 10.1097/MD.0000000000002877 .
  100. Web site: MELD Score (Model For End-Stage Liver Disease) (12 and older) . 2022-03-24 . MDCalc.
  101. Web site: MELDNa/MELD-Na Score for Liver Cirrhosis . 2022-03-24 . MDCalc.
  102. Kartoun U, Corey KE, Simon TG, Zheng H, Aggarwal R, Ng K, Shaw SY . The MELD-Plus: A generalizable prediction risk score in cirrhosis . PLOS ONE . 12 . 10 . e0186301 . 2017 . 29069090 . 5656314 . 10.1371/journal.pone.0186301 . 2017PLoSO..1286301K . free .
  103. Patch D, Armonis A, Sabin C, Christopoulou K, Greenslade L, McCormick A, Dick R, Burroughs AK . Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding . Gut . 44 . 2 . 264–269 . February 1999 . 9895388 . 1727391 . 10.1136/gut.44.2.264 . live . https://web.archive.org/web/20080528225834/http://gut.bmj.com/cgi/content/abstract/44/2/264 . 2008-05-28 .
  104. Web site: Cirrhosis . The Lecturio Medical Concept Library . 28 September 2020 . 9 July 2021 . 9 July 2021 . https://web.archive.org/web/20210709191841/https://www.lecturio.com/concepts/cirrhosis/ . live .
  105. Wadhawan M, Anand AC . Coffee and Liver Disease . Journal of Clinical and Experimental Hepatology . 6 . 1 . 40–46 . March 2016 . 27194895 . 4862107 . 10.1016/j.jceh.2016.02.003 .
  106. Ruiz-Margáin A, Macías-Rodríguez RU, Ríos-Torres SL, Román-Calleja BM, Méndez-Guerrero O, Rodríguez-Córdova P, Torre A . Effect of a high-protein, high-fiber diet plus supplementation with branched-chain amino acids on the nutritional status of patients with cirrhosis . Revista de Gastroenterologia de Mexico . 83 . 1 . 9–15 . January 2018 . 28408059 . 10.1016/j.rgmx.2017.02.005 . 196487820 . free .
  107. McDowell HR, Chuah CS, Tripathi D, Stanley AJ, Forrest EH, Hayes PC . Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study . Alimentary Pharmacology & Therapeutics . 53 . 4 . 531–539 . February 2021 . 33296526 . 10.1111/apt.16189 . 20.500.11820/83f830e0-832f-401e-bfe3-5576d368ea15 . 228089776 . free .
  108. Web site: Treatment of Cirrhosis . NHS. 20 October 2017 .
  109. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA . A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis . The New England Journal of Medicine . 384 . 12 . 1113–1124 . March 2021 . 33185364 . 10.1056/NEJMoa2028395 . 226850568 . free .
  110. Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, Bhandari BR, Gunn N, Caldwell SH, Goodman Z, Wapinski I, Resnick M, Beck AH, Ding D, Jia C, Chuang JC, Huss RS, Chung C, Subramanian GM, Myers RP, Patel K, Borg BB, Ghalib R, Kabler H, Poulos J, Younes Z, Elkhashab M, Hassanein T, Iyer R, Ruane P, Shiffman ML, Strasser S, Wong VW, Alkhouri N . Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH . Hepatology . 73 . 2 . 625–643 . February 2021 . 33169409 . 10.1002/hep.31622 . 226295213 .
  111. Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF . A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH . The New England Journal of Medicine . 385 . 17 . 1547–1558 . October 2021 . 34670042 . 10.1056/NEJMoa2036205 . 1854/LU-8731444 . 239051427 . free . free .
  112. Schweighardt AE, Juba KM . A Systematic Review of the Evidence Behind Use of Reduced Doses of Acetaminophen in Chronic Liver Disease . Journal of Pain & Palliative Care Pharmacotherapy . 32 . 4 . 226–239 . December 2018 . 31206302 . 10.1080/15360288.2019.1611692 . 190535151 .
  113. Bajaj JS, Kamath PS, Reddy KR. The Evolving Challenge of Infections in Cirrhosis. The New England Journal of Medicine. 384. 24. 2317–2330. 10.1056/NEJMra2021808. 34133861. 2021.
  114. Web site: Nonalcoholic Fatty Liver Disease. The Lecturio Medical Concept Library . 15 August 2021.
  115. Björnsson ES . Hepatotoxicity by Drugs: The Most Common Implicated Agents . International Journal of Molecular Sciences . 17 . 2 . 224 . February 2016 . 26861310 . 4783956 . 10.3390/ijms17020224 . free .
  116. Aamann L, Dam G, Rinnov AR, Vilstrup H, Gluud LL. December 2018. Physical exercise for people with cirrhosis. The Cochrane Database of Systematic Reviews. 2018. 12. CD012678. 10.1002/14651858.CD012678.pub2. 6517144. 30575956. Cochrane Hepato-Biliary Group.
  117. Web site: E-medicine liver transplant outlook and survival rates . Emedicinehealth.com . 2009-06-09 . 2009-09-06 . live . https://web.archive.org/web/20090714145002/http://www.emedicinehealth.com/liver_transplant/page11_em.htm . 2009-07-14.
  118. Kamath PS, Kim WR . The model for end-stage liver disease (MELD) . Hepatology . 45 . 3 . 797–805 . March 2007 . 17326206 . 10.1002/hep.21563 . 10440305 . free .
  119. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Soares-Weiser K, Uribe M . Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding . The Cochrane Database of Systematic Reviews . 9 . CD002907 . September 2010 . 2010 . 20824832 . 7138054 . 10.1002/14651858.CD002907.pub2 .
  120. Ferrell B, Connor SR, Cordes A, Dahlin CM, Fine PG, Hutton N, Leenay M, Lentz J, Person JL, Meier DE, Zuroski K . The national agenda for quality palliative care: the National Consensus Project and the National Quality Forum . Journal of Pain and Symptom Management . 33 . 6 . 737–744 . June 2007 . 17531914 . 10.1016/j.jpainsymman.2007.02.024 . free .
  121. Sanchez W, Talwalkar JA . Palliative care for patients with end-stage liver disease ineligible for liver transplantation . Gastroenterology Clinics of North America . 35 . 1 . 201–219 . March 2006 . 16530121 . 10.1016/j.gtc.2005.12.007 .
  122. Poonja Z, Brisebois A, van Zanten SV, Tandon P, Meeberg G, Karvellas CJ . Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management . Clinical Gastroenterology and Hepatology . 12 . 4 . 692–698 . April 2014 . 23978345 . 10.1016/j.cgh.2013.08.027 .
  123. O'Shea RS, Davitkov P, Ko CW, Rajasekhar A, Su GL, Sultan S, Allen AM, Falck-Ytter Y . AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis . English . Gastroenterology . 161 . 5 . 1615–1627.e1 . November 2021 . 34579936 . 10.1053/j.gastro.2021.08.015 . 238202670 . free .
  124. Moore KP, Aithal GP . Guidelines on the management of ascites in cirrhosis . Gut . 55 . Suppl 6 . vi1–v12 . October 2006 . 16966752 . 1860002 . 10.1136/gut.2006.099580 .
  125. Piano S, Tonon M, Angeli P . Management of ascites and hepatorenal syndrome . Hepatology International . 12 . Suppl 1 . 122–134 . February 2018 . 28836115 . 10.1007/s12072-017-9815-0 . 3708859 .
  126. Sellers CM, Nezami N, Schilsky ML, Kim HS . Transjugular intrahepatic portosystemic shunt as a bridge to liver transplant: Current state and future directions . Transplantation Reviews . 33 . 2 . 64–71 . April 2019 . 30477811 . 10.1016/j.trre.2018.10.004 . 53736623 .
  127. Lee EW, Shahrouki P, Alanis L, Ding P, Kee ST . June 2019 . Management Options for Gastric Variceal Hemorrhage . JAMA Surgery . 154 . 6 . 540–548 . 10.1001/jamasurg.2019.0407 . 30942880 . 93000660.
  128. Web site: December 2006 . Gastroscopy – examination of oesophagus and stomach by endoscope . dead . https://web.archive.org/web/20071006035730/http://hcd2.bupa.co.uk/fact_sheets/html/Gastrointestinal.html . 2007-10-06 . 2007-10-07 . BUPA.
  129. Web site: National Digestive Diseases Information Clearinghouse . National Digestive Diseases Information Clearinghouse . November 2004 . Upper Endoscopy . 2007-10-07 . . 2007-10-24 . https://web.archive.org/web/20071024122838/http://digestive.niddk.nih.gov/ddiseases/pubs/upperendoscopy/index.htm . dead .
  130. Web site: What is Upper GI Endoscopy? . dead . https://web.archive.org/web/20070928014913/http://www.gastro.org/wmspage.cfm?parm1=859 . 2007-09-28 . 2007-10-07 . Patient Center -- Procedures . American Gastroenterological Association.
  131. Lockwood . Alan H. . December 2004 . Blood Ammonia Levels and Hepatic Encephalopathy . Metabolic Brain Disease . en . 19 . 3/4 . 345–349 . 10.1023/B:MEBR.0000043980.74574.eb . 15554426 . 27884883 . 0885-7490.
  132. Web site: Ferenci P . Feb 2022 . Hepatic encephalopathy in adults: Treatment . 2022-03-22 . www.uptodate.com.
  133. Vilstrup . Hendrik . Amodio . Piero . Bajaj . Jasmohan . Cordoba . Juan . Ferenci . Peter . Mullen . Kevin D. . Weissenborn . Karin . Wong . Philip . 2014-07-08 . Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver: Vilstrup et al. . Hepatology . en . 60 . 2 . 715–735 . 10.1002/hep.27210. 25042402 .
  134. Elkington . S G . 1970-12-01 . Lactulose. . Gut . en . 11 . 12 . 1043–1048 . 10.1136/gut.11.12.1043 . 0017-5749 . 1553161 . 4929274.
  135. Adachi . J. A. . DuPont . H. L. . 2006-02-15 . Rifaximin: A Novel Nonabsorbed Rifamycin for Gastrointestinal Disorders . Clinical Infectious Diseases . en . 42 . 4 . 541–547 . 10.1086/499950 . 16421799 . 1058-4838.
  136. Bass . Nathan M. . Mullen . Kevin D. . Sanyal . Arun . Poordad . Fred . Neff . Guy . Leevy . Carroll B. . Sigal . Samuel . Sheikh . Muhammad Y. . Beavers . Kimberly . Frederick . Todd . Teperman . Lewis . Hillebrand . Donald . Huang . Shirley . Merchant . Kunal . Shaw . Audrey . 2010-03-25 . Rifaximin Treatment in Hepatic Encephalopathy . New England Journal of Medicine . en . 362 . 12 . 1071–1081 . 10.1056/NEJMoa0907893 . 20335583 . 0028-4793.
  137. Zacharias . Harry D . Kamel . Fady . Tan . Jaclyn . Kimer . Nina . Gluud . Lise Lotte . Morgan . Marsha Y . 2023-07-19 . Cochrane Hepato-Biliary Group . Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis . Cochrane Database of Systematic Reviews . en . 2023 . 7 . CD011585 . 10.1002/14651858.CD011585.pub2 . 10360160 . 37467180.
  138. Merli M, Berzigotti A, Zelber-Sagi S, Dasarathy S, Montagnese S, Genton L, Plauth M, Parés A . January 2019 . EASL Clinical Practice Guidelines on nutrition in chronic liver disease . Journal of Hepatology . 70 . 1 . 172–193 . 10.1016/j.jhep.2018.06.024 . 6657019 . 30144956.
  139. Francoz C, Durand F, Kahn JA, Genyk YS, Nadim MK . Hepatorenal Syndrome . Clinical Journal of the American Society of Nephrology . 14 . 5 . 774–781 . May 2019 . 30996046 . 6500947 . 10.2215/CJN.12451018 .
  140. Kim MY, Choi H, Baik SK, Yea CJ, Won CS, Byun JW, Park SY, Kwon YH, Kim JW, Kim HS, Kwon SO, Kim YJ, Cha SH, Chang SJ . Portal hypertensive gastropathy: correlation with portal hypertension and prognosis in cirrhosis . Digestive Diseases and Sciences . 55 . 12 . 3561–3567 . December 2010 . 20407828 . 10.1007/s10620-010-1221-6 . 24332780 .
  141. Sipeki N, Antal-Szalmas P, Lakatos PL, Papp M . Immune dysfunction in cirrhosis . World Journal of Gastroenterology . 20 . 10 . 2564–2577 . March 2014 . 24627592 . 3949265 . 10.3748/wjg.v20.i10.2564 . free .
  142. Forner A, Llovet JM, Bruix J . Hepatocellular carcinoma . Lancet . 379 . 9822 . 1245–1255 . March 2012 . 22353262 . 10.1016/S0140-6736(11)61347-0 . 24927898 .
  143. Singal AG, Pillai A, Tiro J . Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis . PLOS Medicine . 11 . 4 . e1001624 . April 2014 . 24691105 . 3972088 . 10.1371/journal.pmed.1001624 . free .
  144. Asrani SK, Devarbhavi H, Eaton J, Kamath PS . Burden of liver diseases in the world . Journal of Hepatology . 70 . 1 . 151–171 . January 2019 . 30266282 . 10.1016/j.jhep.2018.09.014 . 52882095 .
  145. Anderson RN, Smith BL . Deaths: leading causes for 2001 . National Vital Statistics Reports . 52 . 9 . 1–85 . November 2003 . 14626726 .
  146. Book: Tamparo C . Diseases of the Human Body . 5th . F. A. Davis Company . 2011 . 978-0-8036-2505-1 . Philadelphia, PA . 422.
  147. Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M, etal . GBD 2017 Cirrhosis Collaborators . The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 . The Lancet. Gastroenterology & Hepatology . 5 . 3 . 245–266 . March 2020 . 31981519 . 7026710 . 10.1016/S2468-1253(19)30349-8 .
  148. .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cirrhosis".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.